FAISAL TAI: Open Payments
NPI 1619381316 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$598 in 22 payments from 11 companies in 2025. Trend: 2023 $8,753 · 2024 $23,897 · 2025 $598
Food & beverage: $598
| Company | Payments | Amount |
|---|---|---|
| Janssen Scientific Affairs, LLC | 1 | $129 |
| Janssen Pharmaceuticals, Inc | 4 | $106 |
| ABBVIE INC. | 5 | $105 |
| Otsuka America Pharmaceutical, Inc. | 3 | $58 |
| Neurocrine BioSciences, Inc. | 2 | $48 |
| Alkermes, Inc. | 2 | $40 |
| Axsome Therapeutics, Inc. | 1 | $26 |
| Luye Pharma (USA) Ltd. | 1 | $24 |
| E.R. Squibb & Sons, L.L.C. | 1 | $22 |
| Corium, LLC | 1 | $21 |
Products named: SPRAVATO, VRAYLAR, REXULTI, INGREZZA, ARISTADA, Auvelity, ERZOFRI EXTENDED-RELEASE, INVEGA SUSTENNA.
Industry payments across TX — which companies pay providers there.
